Literature DB >> 8940448

Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA.

Z Wang1, B G Hansson, O Forslund, L Dillner, M Sapp, J T Schiller, B Bjerre, J Dillner.   

Abstract

To investigate whether cervical mucus antibodies against human papillomavirus (HPV) capsids are associated with the detection of HPV DNA or HPV-related cytological diagnoses, 611 samples of cervical secretions from 359 women referred to a colposcopy clinic were tested by an enzyme-linked immunosorbent assay for the presence of immunoglobulin A (IgA) antibodies against HPV capsids of HPV type 16, 18, or 33 and for the presence of cervical HPV DNA by PCR. Among subjects with at least one cervical sample positive for HPV type 16 (HPV-16) DNA, 28.1% also had at least one HPV-16 IgA-positive cervical sample (odds ratio [OR] = 2.9; P = 0.0003). IgA to HPV-18 was also more common among HPV-18 DNA-positive subjects (OR = 3.1; P = 0.0325) and IgA to HPV-33 was more common among HPV-33 DNA-positive subjects (OR = 4.2; P = 0.0023). Cervical IgA antibodies to HPV-16 were also more common among patients with cervical intraepithelial neoplasia, particularly among patients with cervical intraepithelial neoplasia grade I (P < 0.0005). The data indicate that an HPV type-restricted IgA antibody response against HPV capsids is detectable in cervical mucus and is associated with a concomitant cervical HPV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940448      PMCID: PMC229459          DOI: 10.1128/jcm.34.12.3056-3062.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia.

Authors:  L Wideroff; M H Schiffman; B Nonnenmacher; N Hubbert; R Kirnbauer; C E Greer; D Lowy; A T Lorincz; M M Manos; A G Glass
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

2.  Divergent human papillomavirus type 16 variants are serologically cross-reactive.

Authors:  G Cheng; J P Icenogle; R Kirnbauer; N L Hubbert; M E St Louis; C Han; E I Svare; S K Kjaer; D R Lowy; J T Schiller
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

3.  Identification of human papillomavirus seroconversions.

Authors:  A Wikström; G J van Doornum; W G Quint; J T Schiller; J Dillner
Journal:  J Gen Virol       Date:  1995-03       Impact factor: 3.891

4.  Genital HPV infection not a local but a regional infection: experience from a female teenage group.

Authors:  P Rymark; O Forslund; B G Hansson; K Lindholm
Journal:  Genitourin Med       Date:  1993-02

5.  Antibodies against papillomavirus antigens in cervical secretions from condyloma patients.

Authors:  L Dillner; A Fredriksson; E Persson; O Forslund; B G Hansson; J Dillner
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

6.  Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma.

Authors:  P Heino; C Eklund; V Fredriksson-Shanazarian; S Goldman; J T Schiller; J Dillner
Journal:  J Natl Cancer Inst       Date:  1995-03-15       Impact factor: 13.506

7.  Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens.

Authors:  K Elfgren; P Bistoletti; L Dillner; J M Walboomers; C J Meijer; J Dillner
Journal:  Am J Obstet Gynecol       Date:  1996-03       Impact factor: 8.661

8.  Human papilloma virus types in routine cytological screening and at colposcopic examinations.

Authors:  B G Hansson; O Forslund; B Bjerre; K Lindholm; E Nordenfelt
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1993-11       Impact factor: 2.435

9.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

Authors:  R Kirnbauer; N L Hubbert; C M Wheeler; T M Becker; D R Lowy; J T Schiller
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

View more
  5 in total

1.  Collection of cervical secretions does not adversely affect Pap smears taken immediately afterward.

Authors:  A Hildesheim; M C Bratti; R P Edwards; M Schiffman; A C Rodriguez; R Herrero; M Alfaro; L A Morera; S V Ermatinger; B T Miller; P A Crowley-Nowick
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

2.  Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract.

Authors:  Geert Zegels; Geert Aa Van Raemdonck; Wiebren Aa Tjalma; Xaveer Wm Van Ostade
Journal:  Proteome Sci       Date:  2010-12-08       Impact factor: 2.480

3.  Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women.

Authors:  Elham Hassen; Devendra Bansal; Randa Ghdira; Anouar Chaieb; Hedi Khairi; Abdelfattah Zakhama; Sami Remadi; Johan Hoebeke; Ali A Sultan; Lotfi Chouchane
Journal:  J Transl Med       Date:  2020-07-29       Impact factor: 5.531

4.  Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.

Authors:  Ralph-Sydney Mboumba Bouassa; Hélène Péré; Camélia Gubavu; Thierry Prazuck; Mohammad-Ali Jenabian; David Veyer; Jean-François Meye; Antoine Touzé; Laurent Bélec
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

Review 5.  Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature.

Authors:  Jade Pattyn; Severien Van Keer; Wiebren Tjalma; Veerle Matheeussen; Pierre Van Damme; Alex Vorsters
Journal:  Papillomavirus Res       Date:  2019-09-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.